BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6161 related articles for article (PubMed ID: 20197344)

  • 21. Selection of sublobar resection for c-stage IA non-small cell lung cancer based on a combination of structural imaging by CT and functional imaging by FDG PET.
    Yoshioka M; Ichiguchi O
    Ann Thorac Cardiovasc Surg; 2009 Apr; 15(2):82-8. PubMed ID: 19471220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
    Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
    Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
    Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer].
    Yang WF; Tan GZ; Fu Z; Yu JM
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):925-8. PubMed ID: 20193335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detecting recurrence of gastric cancer: the value of FDG PET/CT.
    Park MJ; Lee WJ; Lim HK; Park KW; Choi JY; Kim BT
    Abdom Imaging; 2009 Jul; 34(4):441-7. PubMed ID: 18543017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
    Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
    Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
    Bury T; Corhay JL; Duysinx B; Daenen F; Ghaye B; Barthelemy N; Rigo P; Bartsch P
    Eur Respir J; 1999 Dec; 14(6):1376-80. PubMed ID: 10624770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 309.